BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27723100)

  • 1. How we manage patients with hereditary haemochromatosis.
    Rombout-Sestrienkova E; van Kraaij MG; Koek GH
    Br J Haematol; 2016 Dec; 175(5):759-770. PubMed ID: 27723100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Course of iron parameters in HFE-hemochromatosis patients during initial treatment with erythrocytapheresis compared to phlebotomy.
    Rombout-Sestrienkova E; Koek GH; Neslo R; van Kraaij M; Menheere PP; Masclee A; Swinkels DW
    J Clin Apher; 2016 Dec; 31(6):564-570. PubMed ID: 26878994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromatosis.
    Sundic T; Hervig T; Hannisdal S; Assmus J; Ulvik RJ; Olaussen RW; Berentsen S
    Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s84-9. PubMed ID: 24333062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Erythrocytapheresis for hereditary haemochromatosis].
    Rombout-Sestrienkova E; van Deursen CT; Janssen MC; van Kraaij MG; de Leeuw PW; Koek GH
    Ned Tijdschr Geneeskd; 2012; 156(26):A4745. PubMed ID: 22759710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: the iron overload syndromes.
    Siddique A; Kowdley KV
    Aliment Pharmacol Ther; 2012 Apr; 35(8):876-93. PubMed ID: 22385471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and management of hereditary haemochromatosis.
    van Bokhoven MA; van Deursen CT; Swinkels DW
    BMJ; 2011 Jan; 342():c7251. PubMed ID: 21248018
    [No Abstract]   [Full Text] [Related]  

  • 7. A predictive model for estimating the number of erythrocytapheresis or phlebotomy treatments for patients with naïve hereditary hemochromatosis.
    Rombout-Sestrienkova E; Winkens B; van Kraaij M; van Deursen CTBM; Janssen MCH; Rennings AMJ; Evers D; Kerkhoffs JL; Masclee A; Koek GH
    J Clin Apher; 2021 Jun; 36(3):340-347. PubMed ID: 33368569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and treatment of hereditary hemochromatosis: an update.
    Kanwar P; Kowdley KV
    Expert Rev Gastroenterol Hepatol; 2013 Aug; 7(6):517-30. PubMed ID: 23985001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The modified iron avidity index: a promising phenotypic predictor in HFE-related haemochromatosis.
    Verhaegh PL; Moris W; Koek GH; van Deursen CT
    Liver Int; 2016 Oct; 36(10):1535-9. PubMed ID: 26992127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemochromatosis.
    Adams PC; Barton JC
    Lancet; 2007 Dec; 370(9602):1855-60. PubMed ID: 18061062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy.
    Bring P; Partovi N; Ford JA; Yoshida EM
    Pharmacotherapy; 2008 Mar; 28(3):331-42. PubMed ID: 18294113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effectiveness of therapeutic erythrocytapheresis to achieve iron depletion in hereditary type 1 hemochromatosis: report of 30 cases].
    Poullin P; Lefèvre PA
    Transfus Clin Biol; 2011 Dec; 18(5-6):553-8. PubMed ID: 22019606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial.
    Rombout-Sestrienkova E; Nieman FH; Essers BA; van Noord PA; Janssen MC; van Deursen CT; Bos LP; Rombout F; van den Braak R; de Leeuw PW; Koek GH
    Transfusion; 2012 Mar; 52(3):470-7. PubMed ID: 21848963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of erythrocytapheresis and low-dose erythropoietin for treatment of hemochromatosis.
    Brückl D; Kamhieh-Milz S; Kamhieh-Milz J; Salama A
    J Clin Apher; 2017 Jun; 32(3):170-174. PubMed ID: 27271482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic erythrocytapheresis versus phlebotomy in the initial treatment of hereditary hemochromatosis - A pilot study.
    Rombout-Sestrienkova E; van Noord PA; van Deursen CT; Sybesma BJ; Nillesen-Meertens AE; Koek GH
    Transfus Apher Sci; 2007 Jun; 36(3):261-7. PubMed ID: 17569592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hereditary haemochromatosis: novel genes, novel diseases and hepcidin].
    Bergmans JP; Kemna EH; Janssen MC; Jacobs EM; Stalenhoef AF; Marx JJ; Swinkels DW
    Ned Tijdschr Geneeskd; 2007 May; 151(20):1121-7. PubMed ID: 17557668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Importance of hereditary haemochromatosis in the care of diabetes mellitus].
    Wittmann I; Wagner L; Markó L; Tamaskó M; Laczy B; Márton M; Cseh J; Melegh B
    Orv Hetil; 2007 Jan; 148(3):111-5. PubMed ID: 17289614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and management of hereditary hemochromatosis.
    Salgia RJ; Brown K
    Clin Liver Dis; 2015 Feb; 19(1):187-98. PubMed ID: 25454304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythrocytapheresis plus erythropoietin: an alternative therapy for selected patients with hemochromatosis and severe organ damage.
    Mariani R; Pelucchi S; Perseghin P; Corengia C; Piperno A
    Haematologica; 2005 May; 90(5):717-8. PubMed ID: 15921401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythrocytapheresis versus phlebotomy in the maintenance treatment of HFE hemochromatosis patients: results from a randomized crossover trial.
    Rombout-Sestrienkova E; Winkens B; Essers BA; Nieman FH; Noord PA; Janssen MC; van Deursen CT; Boonen A; Reuser-Kaasenbrood EP; Heeremans J; van Kraaij M; Masclee A; Koek GH
    Transfusion; 2016 Jan; 56(1):261-70. PubMed ID: 26358375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.